CAR T Cells Encouraging for Diffuse Large B-Cell Lymphoma CAR T Cells Encouraging for Diffuse Large B-Cell Lymphoma

Results from phase 2 studies of two anti-CD19 therapies for relapsed/refractory DLBCL show impressive responses, as well as adverse events that were ' reversible. 'Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news